MARKET

ARDX

ARDX

Ardelyx
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.310
-0.030
-2.24%
After Hours: 1.300 -0.01 -0.76% 19:59 09/17 EDT
OPEN
1.358
PREV CLOSE
1.340
HIGH
1.360
LOW
1.290
VOLUME
7.83M
TURNOVER
--
52 WEEK HIGH
9.23
52 WEEK LOW
1.250
MARKET CAP
135.09M
P/E (TTM)
-0.9979
1D
5D
1M
3M
1Y
5Y
2 Falling Knives to Catch
GuruFocus News · 9h ago
Irritable Bowel Syndrome Drugs Market: Expected CAGR, Top Manufacturers and Consumer Analysis across the Region and Globe, Opportunities and Growth till 2029
Research Nester published a report titled which delivers detailed overview of the irritable bowel drugs market in terms of market segmentation by type, by product, by end user and by region.
AmericaNewsHour · 09/08 06:26
ARDX DEADLINE REMINDER: Kessler Topaz Meltzer & Check, LLP - Important October 4, 2021 Deadline Reminder for Ardelyx Inc. Investors
Radnor, Pennsylvania--(Newsfile Corp. - September 4, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds Ardelyx Inc. (NASDAQ: ARDX) ("Ardelyx") investors that a securities fraud class action lawsuit has been filed against Ardelyx on behalf ...
Newsfile · 09/04 22:25
Irritable Bowel Syndrome Drugs Market- Up-To-Date Statistics, Development Areas And Emerging Opportunities Worldwide 2029
Research Nester published a report titled which delivers detailed overview of the irritable bowel drugs market in terms of market segmentation by type, by product, by end user and by region.
AmericaNewsHour · 09/03 13:51
BRIEF-Ardelyx Announces Publication Of 52-Week Phase 3 PHREEDOM Trial
reuters.com · 09/03 12:08
Ardelyx Highlights Publication Of 52-Week Phase 3 PHREEDOM Trial
Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal
Benzinga · 09/03 12:01
Ardelyx Announces Publication of 52-Week Phase 3 PHREEDOM Trial
and , /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today...
PR Newswire - PRF · 09/03 12:00
Ardelyx Unveils Plans for Common Stock Offering of up to $150 Million
MT Newswires · 08/18 06:27
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ARDX. Analyze the recent business situations of Ardelyx through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ARDX stock price target is 6.21 with a high estimate of 15.00 and a low estimate of 2.000.
EPS
Institutional Holdings
Institutions: 173
Institutional Holdings: 92.53M
% Owned: 89.73%
Shares Outstanding: 103.12M
TypeInstitutionsShares
Increased
45
7.52M
New
25
3.70M
Decreased
38
9.02M
Sold Out
24
2.24M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.49%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Non-Executive Chairman/Independent Director
David Mott
President/Chief Executive Officer/Director
Michael Raab
Chief Financial Officer/Chief Accounting Officer
Justin Renz
Chief Administrative Officer
Elizabeth Grammer
Chief Scientific Officer
Jeffrey Jacobs
Other
Robert Blanks
Other
Susan Rodriguez
Other
David Rosenbaum
Independent Director
Robert Bazemore
Independent Director
William Bertrand
Independent Director
Muna Bhanji
Independent Director
Geoffrey Block
Independent Director
Onaiza Cadoret-Manier
Independent Director
Jan Lundberg
Independent Director
Richard Rodgers
No Data
About ARDX
Ardelyx, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of medicines to improve treatment for people with kidney and cardiorenal diseases. The Company's product pipeline includes Tenapanor, IBSRELA, RDX013 Program, and RDX020 Program. The Tenapanor is a medicine for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor for the control of serum phosphorus has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). RDX013 Program is a small molecule potassium secretagogue program for the potential treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis. It has a discovery program targeting the inhibition of intestinal bicarbonate exchange for the treatment of metabolic acidosis.

Webull offers kinds of Ardelyx Inc stock information, including NASDAQ:ARDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARDX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ARDX stock methods without spending real money on the virtual paper trading platform.